Press Releases<< Back
AlloSure Detects Active Rejection in Kidney Transplant Patients
AlloSure is a clinical-grade proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in solid organ transplant recipients. The DART clinical trial is a landmark study for
Key takeaways from the data:
- AlloSure differentiates "Active Rejection" from "Non Rejection"
- Assay has sensitivity of 59% and specificity of 85% at a 1% threshold
- AlloSure provides PPV of 60% at a 1% threshold and 85% at a 3% threshold
- AlloSure provides NPV of 84% at a 1% threshold and 80% at a 3% threshold
A summary of the data can be found in the following poster presentation (FR-PO1133).
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release contains forward-looking statements including, but not limited to our business, research, development and commercialization efforts and anticipated future financial results. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including the continued successful development and planned commercialization of AlloSure, that are described in our filings with the
Investor Relations Contact
Jamar Ismail, Vice President Westwicke Partners, LLCT: +1 415-513-1282 E: email@example.com
News Provided by Acquire Media